Discover Research Partnerships with Boehringer Ingelheim
Our research teams know that they can only tackle some of the most important challenges in medicine today if we work together with colleagues outside our organisation. We invite academic institutions, non-profit research centres and external industry partners to help us deliver a better future for patients.
Novartis reboots brain division doi:10.1038/502153a After years in the doldrums, research into neurological disorders is about to undergo a major change of direction. Full Text
Data-crunch highlights potential transplant drugs doi:10.1038/nature.2013.13944 Widely prescribed statin could have alternative applications. Full Text
Secrets of trial data revealed doi:10.1038/502154a Records of side effects seen in clinical tests are missing from publicly available documents. Full Text
Amgen swallows Onyx whole doi:10.1038/nbt1013-859 Amgen agreed to acquire Onyx Pharmaceuticals in one of the largest takeovers in biotech history, signaling its hunger for late-stage products and expanded interest in pipeline opportunities for the large and growing oncology market. Full Text
NSD2 momentum doi:10.1038/scibx.2013.1083 NSD2 has been genetically linked to multiple myeloma for years, but drug discovery efforts against the target have floundered. Two teams provide compelling evidence that inhibiting the protein could help treat haematological cancers. Full Text
Pharmaceutical forecasting: throwing darts? doi:10.1038/nrd4127 Forecasting of the future commercial value of drugs is a crucial activity that affects many decisions by pharmaceutical companies. However, this analysis indicates that many forecasts are wrong, often substantially. Full Text
Anticancer drugs: Stapled peptide reactivates p53 doi:10.1038/nrd4133 The stapled α-helical peptide ATSP-7041 - which is a specific dual inhibitor of MDM2 and MDMX - effectively induces p53-dependent apoptosis and inhibits cell proliferation in mouse models of human tumours. Full Text
Biotechnology: Rice-derived rotavirus antibody shows promise doi:10.1038/nrd4131 Researchers have genetically engineered rice to produce high yields of a rotavirus-specific antibody fragment in the seeds. This antibody was effective in treating and preventing rotavirus-induced gastrointestinal symptoms in mice. Full Text
Neurodegenerative diseases: New kinase targets for Alzheimer's disease doi:10.1038/nrd4132 Two recent studies show that inhibiting kinases involved in the regulation of amyloid precursor protein processing or protein synthesis by eukaryotic translation initiation factor 2α attenuates disease progression in mice. Full Text
Considerations for the successful co-development of targeted cancer therapies and companion diagnostics doi:10.1038/nrd4101 The authors discuss issues relating to the co-development of targeted cancer therapies and companion diagnostics that were not covered in depth in the draft guidance released by the US FDA in 2011. They also propose potential strategies that will be useful to mitigate challenges and to help guide the future co-development of drugs and diagnostics. Full Text
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology doi:10.1038/nrc3580 Anaplastic lymphoma kinase (ALK) is commonly altered - through mutation, overexpression or translocation - in many types of cancer, but the role of ALK signalling in mammalian cells and tumours remains enigmatic. What can we learn from model systems? And what progress has been made in targeting this receptor tyrosine kinase? Full Text
p11 and its role in depression and therapeutic responses to antidepressants doi:10.1038/nrn3564 Recent studies have shown that the protein p11 (also known as S100A10) has an important role in depression-like behaviour and antidepressant actions. Greengard and colleagues discuss the molecular and cellular mechanisms that may underlie this role. Full Text
Macrophages in atherosclerosis: a dynamic balance doi:10.1038/nri3520 In this Review, the authors provide a comprehensive overview of the role of macrophage dynamics in determining the initiation, progression and regression of atherosclerotic inflammation. Understanding the factors that determine the inflammatory state of the plaque may help to identify potential therapeutic targets for plaque regression. Full Text
Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant)
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.
No comments:
Post a Comment